Dalteparin sodium
(Redirected from
Dalteparin
) | ||
| Clinical data | ||
|---|---|---|
| Trade names | Fragmin | |
| AHFS/Drugs.com | Monograph | |
| Pregnancy category |
| |
Subcutaneous | ||
| ATC code | ||
| Legal status | ||
| Legal status | ||
ECHA InfoCard | 100.110.590 | |
Dalteparin is a
It is normally administered by self-injection.The CLOT study, published in 2003, showed that in patients with malignancy and acute
unfractionated heparin in preventing blood clots.[5]
Heparins are
kidney function is reduced.[6] Approximately 70% of dalteparin is excreted through kidneys based on animal studies.[7]
In May 2019, the U.S. Food and Drug Administration (FDA) approved Fragmin injection to reduce the recurrence of symptomatic VTE in pediatric patients one month of age and older.[8] It is on the World Health Organization's List of Essential Medicines.[9]
References
- ^ a b "Dalteparin (Fragmin) Use During Pregnancy". Drugs.com. 27 November 2019. Retrieved 1 June 2020.
- ^ Dalteparin - Subcutaneous Injection, HealthLinkBC | https://www.healthlinkbc.ca/medications/fdb0271 Archived 2021-05-03 at the Wayback Machine
- ^ Pfizer Medical Information: Fragmin Pharmacodynamics | https://www.pfizermedicalinformation.ca/en-ca/fragmin/action-and-clinical-pharmacology# Archived 2021-05-07 at the Wayback Machine
- PMID 12853587.
- PMID 21417952.
- S2CID 1513885.
- ^ Pfizer Medication Information: Fragmin Pharmacokinetics | https://www.pfizermedicalinformation.ca/en-ca/fragmin/action-and-clinical-pharmacology# Archived 2021-05-07 at the Wayback Machine
- ^ "FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots, PM FDA, May 16, 2019". U.S. Food and Drug Administration (FDA). Retrieved 17 May 2019.
- hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
External links
- "Dalteparin sodium". Drug Information Portal. U.S. National Library of Medicine.
